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Background: For postmenopausal women, the main reason to start hormone therapy (HT) is to reduce menopausal
symptoms and to improve quality of life (QOL). The aim of this study was to analyse the impact of HT on different
aspects of symptom experience and QOL during a randomised trial.
A total of 1823 postmenopausal women were recruited into the Estonian Postmenopausal Hormone Therapy (EPHT)
trial in 1999–2001. Women were randomised to blind HT, open-label HT, placebo or non-treatment arm. After one
year in the trial, a questionnaire was mailed and 1359 women (75%) responded, 686 in the HT arms and 673 in the
non-HT arms. Mean age at filling in the questionnaire was 59.8 years. The questionnaire included Women's Health
Questionnaire (WHQ) to assess menopause specific QOL of middle-aged women together with a 17-item
questionnaire on symptoms related to menopause, a question about painful intercourse, and a question about
women's self-rated health.
Results: After one year in the trial, fewer women in the HT arms reported hot flashes, trouble sleeping, and
sweating on the symptom questionnaire. According to WHQ, women in the HT arms had fewer vasomotor
symptoms, sleep problems, and problems with sexual behaviour, but more menstrual symptoms; HT had no effect
on depression, somatic symptoms, memory, attractiveness, or anxiety. A smaller proportion of women reported
painful intercourse in the HT arms. There were no significant differences between the trial arms in women’s self-
rated subjective health.
Conclusions: The results from the EPHT trial confirm that HT is not justified for treating symptoms, other than
vasomotor symptoms, among postmenopausal women. WHQ proved to be a useful and sensitive tool to assess
QOL in this age group of women.
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Based on results from long-term randomised trials, the
main indication for hormone therapy (HT) among post-
menopausal women is currently the treatment of meno-
pausal symptoms [1]. At the same time, HT can have
adverse outcomes, such as vaginal bleeding and breast ten-
derness [2], so its overall benefit on subjective well-being
can be estimated by comparing symptom experience as* Correspondence: piret.veerus@tai.ee
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reproduction in any medium, provided the orwell as the quality of life (QOL) of women using HT with
those who do not.
The aim of the present study, which was part of the
Estonian Postmenopausal Hormone Therapy (EPHT)
trial, was to determine whether women receiving HT in
a randomised trial experienced fewer symptoms and bet-
ter QOL after one year of use than women receiving a
matched placebo or no drug. Menopause specific QOL,
assessed using the Women’s Health Questionnaire
(WHQ) [3], was defined as women’s perceptions of
their physical and emotional well being. Earlier, QOL
has been reported in the EPHT trial at year two using
EuroQoL [3] which is a generic health-related QOL
measurement tool.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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assessed using a mailed questionnaire which included
the Women’s Health Questionnaire (WHQ) [4], which
has been developed to investigate psychological and
somatic symptoms experienced by peri- and postmeno-
pausal women and its psychometric properties have
already been well documented [5,6]. In addition, infor-
mation on self-rated health status, specific symptoms
related to menopause and painful intercourse was com-
pared among women in different trial arms.
In previous studies, the effect of HT on QOL among
postmenopausal women has been studied in the WISDOM
trial in the United Kingdom and in the PEPI trial and
the WHI trial in the United States [2,7–9]. All these
trials reported a positive effect of HT on vasomotor
symptoms. The participants in the EPHT trial were
younger than the women participating in the WISDOM
and WHI trial, and the number of participants in the
PEPI trial was relatively small. Despite the age differ-
ences the results from the EPHT Trial are consistent
with previous findings from other trials.
Methods
Women were recruited into the trial by means of a ques-
tionnaire sent to all 50-64 year old Estonian speaking
women in two areas (Tallinn and Tartu and their sur-
rounding counties) in 1999-2001 (n = 39,713) together
with an invitation to participate in a randomised pre-
ventive HT trial. They were sent an information leaflet
containing information on HT available at that time and
a detailed description of the trial, inviting women toInvitation 
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Figure 1 EPHT trial flow chart.participate in this long-term trial studying the effects of
HT on women’s health. The names and addresses were
obtained from the Estonian population registry. A
detailed description of the recruitment procedure, inclu-
sion and exclusion criteria has been published elsewhere.
[10] Women were asked about their education, living
area, marital status, health status, last menstrual period
(LMP), views about menopause, and 17 different symp-
toms that have been associated with menopause. Women
who responded and were eligible according to the ques-
tionnaire data (n = 4,295) were randomised to one of the
four trial arms: either to blind HT arm, placebo arm,
non-blind HT arm or non-treatment arm (Figure 1), and
then invited to the baseline assessment.
For the present analysis, women in the blind and the
non-blind HT arms were combined and these arms were
named HT arms, whereas women participating in the
placebo and the non-treatment arm were analysed to-
gether and this group was named non-HT arms. From
the 2,383 women who came to see the trial physician,
1,823 were recruited after secondary assessment of eligi-
bility (918 to the HT arms and 905 to the non-HT arms).
Regardless their hysterectomy status (13% of women
had undergone subtotal hysterectomy), women in the
HT arms received 0.625 mg conjugated oestrogen (CEE)
plus 2.5 mg medroxyprogesterone acetate (MPA), or
0.625 mg CEE and 5 mg of MPA if they were within
3 years from their last period. Women in the non-HT
arms received either placebo or no treatment. At the end
of the first trial year, nearly half of the women in the HT
arms reported to have used more than 80% of their trialletter
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Table 1 Comparison of first year survey respondents’
background characteristics in different trial arms, EPHT
Trial
Background
characteristic
Non-HT
armsN=673
HT
armsN=686
p-value
Age group, yrs 0.004*
50-54 86 (13%) 117 (17%)
55-59 226 (34%) 261 (38%)
60+ 361 (54%) 308 (45%)
Age, yrs 0.011†
mean 60.1 59.5
median 60.5 60.5
SD 4.0 4.0
Education, yrs 0.213*
<= 12 450(67%) 436 (64%)
>12 222 (33%) 248 (36%)
Marital status 0.719*
married or co-habiting 420 (63%) 432 (63%)
single 39 (6%) 46 (7%)
divorced or widowed 208 (31%) 203 (30%)
Duration of
menopause, yrs
0.184*
<= 3 61 (9%) 77 (11%)
>3 612 (91%) 608 (89%)
* χ2-test.
† t-test.
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using 10-79% of allocated treatment. In the non-HT
arms, very few women (2% used it for more than 80% of
trial duration) started HT, mainly due to menopausal
symptoms [11].
After one year in the trial women received a postal
questionnaire and 1,359 (74.5%) responded, 686 in HT
and 673 in non-HT arms. Women were asked about
symptoms related to menopause with a 17-item symp-
tom list (the same as at baseline), and about menopause
specific QOL using the WHQ, the same version as used
in the UK in the WISDOM-trial [7]. Self-rated health
status was to be ranked as very good, good, moderate,
satisfactory, poor, or very poor.
The WHQ is a 36 item scale developed to measure
emotional and physical symptoms in middle-aged
women and it contains nine subscales. The WHQ was
translated into Estonian by two Estonian researchers
with good English skills. The feasibility of the translation
was tested by a few Estonian lay women aged 50-65 years,
and they had no difficulties completing on the question-
naire. Later, the questionnaire was back-translated into
English by a native English speaking Estonian translator.
The WHQ subscales include: depressed mood (7 items),
anxiety/fears (4 items), sleep problems (3 items), somatic
symptoms (7 items), menstrual symptoms (4 items),
vasomotor symptoms (2 items), memory/concentration
(3 items), attractiveness (2 items), sexual behaviour
(3 items). The attractiveness subscale includes ques-
tions about self-esteem. The questionnaire answers
have a 4-point scale: 1 = yes, definitely, 2 = yes, some-
times, 3 = no, not much and 4 = no, not at all. Accord-
ing to the scale author’s recommendation, item scores
are transformed into a dichotomous scale: if the re-
sponse is 1 or 2, it is scored 0. If the response is 3 or 4,
it is scored 1. For each subscale the mean is calculated;
0 is interpreted as good and 1 as poor quality of life.
For certain items the scoring is reversed as some items
are worded positively and some negatively [6].
The statistical significance of the differences between the
different arms was determined using t-test, χ2-tests,
Wilcoxon rank sum tests, and odds ratios with 95% confi-
dence intervals. All analyses were done by intention-
to-treat principle. No adjustment was used during the
statistical analysis. Correlation between sleeping problems
and vasomotor symptoms was assessed by Pearson correl-
ation coefficient. The software used was SAS version 9.
Results
The overall response rate to the first year questionnaire
was 74.5%. There were no differences between the trial
arms in response rate. In the blind HT arm, 315 women
(75.9%), in the placebo arm, 278 women (73.0%), in the
non-blind HT arm, 371 women (73.8%), and in the non-treatment arm, 395 women (75.4%) returned the mailed
questionnaire.
There were no differences between the respondents in
different trial arms regarding their education (35% had a
university degree), marital status (63% being married or
cohabiting) or years since menopause (about one tenth
of women were within 3 years from menopause)
(Table 1). The mean age of respondents in the HT arms
was statistically significantly lower than that in the non-
HT arms (59.5 versus 60.1 years, SD 4.0), still the median
age of respondents was the same in HT and non-HT
arms and there was no difference between the trial arms
as regards time since menopause. Also, the mean age of
all women participating in the HT arms of the trial was a
bit lower than those in the non-HT arms. Detailed base-
line characteristics of trial participants are presented
elsewhere [10].
The means for the WHQ scales were compared at the
end of the first trial year in different arms (Table 2).
Women in HT arms had better scores for vasomotor
symptoms (p< 0.0001), sleep problems (p = 0.005) and
sexual behaviour (p = 0.001). A separate analysis showed
that women with vasomotor symptoms tended to report
sleep problems (r = 0.28, p< 0.001), in HT arms (r =0.29,
<0.001) as well as in non-HT arms (r = 0.25, p< 0.001).
Table 2 Quality of life according to mean scales of WHQ
at the end of the first trial year, EPHT Trial
Variable Non-HT arms HT arms p-value* p-value†
Mean(SE) Mean(SE)
Depressed mood 0.22(0.01) 0.21(0.01) 0.308 0.539
Somatic symptoms 0.40(0.01) 0.39(0.01) 0.212 0.282
Memory/concentration 0.42(0.01) 0.41(0.01) 0.447 0.490
Vasomotor symptoms 0.36(0.01) 0.21(0.01) <0.0001 <0.0001
Anxiety/fear 0.27(0.01) 0.27(0.01) 0.519 0.642
Sexual behaviour 0.46(0.02) 0.36(0.02) 0.001 <0.001
Sleep problems 0.39(0.01) 0.34(0.01) 0.005 0.005
Menstrual symptoms 0.25(0.01) 0.28(0.01) 0.027 0.017
Attractiveness 0.53(0.01) 0.53(0.01) 0.811 0.791
* Wilcoxon rank sum test.
† t-test.
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for depressed mood, somatic symptoms, memory/
concentration, anxiety/fears, and attractiveness subscales.
However, women in HT arms had higher mean scales for
menstrual symptoms (p= 0.02).
When asking about specific symptoms within past two
weeks, fewer women in the HT arms reported sweating
(OR=0.69; 95%CI: 0.55-0.86), trouble sleeping (0.63;0.49-
0.80), and hot flashes (0.28;0.21-0.37) at the end of the first
trial year, compared with women in the non-HT arms
(Table 3). There were no differences in the reporting of
other symptoms. In general the symptoms that were mostTable 3 Number and proportion of women reporting symptom
in different trial arms, EPHT Trial
Symptom Non-HT arms
Lack of energy 347 (51.6%)
Aches/stiffness in joints 374 (55.6%)
Backaches 264 (39.2%)
Headaches 235 (34.9%)
Irritability 210 (31.2%)
Sweating 254 (37.7%)
Trouble sleeping 220 (32.7%)
Diarrhoea or constipation 155 (23.0%)
Feeling blue or depressed 142 (21.1%)
Dizzy spells 149 (22.1%)
Water retention 97 (14.4%)
Sore throat 67 (10.0%)
Hot flashes 219 (32.5%)
Shortness of breath 90 (13.4%)
Persistent cough 68 (10.1%)
Upset stomach 85 (12.6%)
Loss of appetite 22 (3.3%)
* χ2-test.
† Non-HT arms as a reference group.often reported by respondents were aches or stiffness in
joints, lack of energy and backache.
At the end of the first trial year, very few women com-
plained about painful intercourse; those in HT arms
reported painful intercourse less frequently than women
in the non-HT arms (p< 0.04), while the number of
women who were not sexually active (about one quarter)
was nearly the same in all arms of the trial (Table 4).
There were no differences between the trial arms in
self-rated health status (Table 5). More than one third of
women stated their health was good or very good, and
more than half moderate or satisfactory. The number of
women who stated their health to be poor or very poor
was very small.
Discussion
Women participating in the EPHT Trial were generally
younger than those in the WHI and WISDOM trials
[2,7,8,10]. The results from these trials show that HT
improves specific symptoms of menopause. However, no
effect of HT on self-rated health status or any other psy-
chological (anxiety, depressed mood, memory/concentra-
tion) or somatic symptom was observed.
The mean age at recruitment in the EPHT trial was
59 years, whereas in the WISDOM trial it was 64 years
[7]. The response rate in the EPHT trial was 75% com-
pared to the 57% in the UK trial. The same WHQ ques-
tionnaire was used both in the EPHT trial and in the
WISDOM trial to assess health related QOL. Combineds within past two weeks at the end of the first trial year
HT arms p-value* OR (95 % CI)†
379 (55.3%) 0.173 1.16(0.94-1.44)
376 (54.8%) 0.778 0.97(0.78-1.20)
263 (38.3%) 0.737 0.96(0.77-1.20)
236 (34.4%) 0.842 0.98(0.78-1.22)
204 (29.7%) 0.557 0.93(0.74-1.18)
202 (29.5%) 0.001 0.69(0.55-0.86)
160 (23.3%) <0.001 0.63(0.49-0.80)
158 (23.0%) 1.000 1.00(0.78-1.29)
149 (21.7%) 0.780 1.04(0.80-1.34)
139 (20.3%) 0.397 0.89(0.69-1.16)
110 (16.0%) 0.405 1.13(0.84-1.53)
88 (12.8%) 0.096 1.33(0.95-1.86)
82 (12.0%) <0.001 0.28(0.21-0.37)
85 (12.4%) 0.589 0.92(0.67-1.26)
69 (10.1%) 0.978 1.00(0.70-1.42)
72 (10.5%) 0.218 0.81(0.58-1.13)
20 (2.9%) 0.707 0.89(0.48-1.65)
Table 4 Number and proportion of women reporting
painful intercourse during the first trial year in different
trial arms, EPHT Trial
Non-HT arms HT arms p-value*
Pain 57 (8.6%) 35 (5.2%) 0.045
No pain 427 (64.5%) 445 (66.0%)
No intercourse 178 (26.9%) 194 (28.8%)
* χ2-test.
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toms, sexual and sleep problems both in the WISDOM
trial and in the EPHT trial after one year of use. Similarly
in both trials, no significant differences were found in
other menopausal symptoms, depression, or overall qual-
ity of life [7].
The mean age in the WHI trial at recruitment was
63 years. The response rate to different questions ranged
from 87% to 90% in the WHI trial. QOL was assessed with
the use of the RAND 36-item health survey. In the WHI
trial, more women assigned to combined HT and symp-
tomatic at baseline reported relief of hot flashes, night
sweats, vaginal dryness at the end of the first trial year, but
women in HT arms were more likely to develop breast
tenderness, vaginal discharge, and headaches [2]. HT had
no effect on depression, somatic symptoms, memory, or
anxiety [2]. The use of HT was not associated with a
meaningful benefit in QOL; there was only a small benefit
in terms of sleep disturbance, physical functioning, and
bodily pain after one year in trial [8]. Among women 50 to
54 years of age with moderate to severe symptoms at base-
line, combined HT improved vasomotor symptoms and
had a small benefit in terms of sleep disturbance, but not
in other quality-of-life outcomes [8].
The mean age of women participating in the PEPI Trial
was 56.1 years at baseline, and 52 symptoms were self-
reported according to a check-list at year one and three.
The 875 women participating in the trial were assigned to
one of the five trial arms, and analysis was restricted to ad-
herent women only. No baseline assessment of symptoms
was reported. The results from the PEPI trial suggested a
protective effect of postmenopausal HT for vasomotor
symptoms, an increase in breast discomfort among users
of progestin-containing regimens, and little influence on
anxiety, cognition, or affect [9].Table 5 Women’s self-rated health status in different trial
arms at the end of the first trial year, EPHT Trial
Non-HT arms HT arms p-value*
0.423
Very good, good 219 (33.3%) 239 (35.4%)
Moderate, satisfactory 412 (62.6%) 416 (61.6%)
Poor, very poor 27 (4.1%) 20 (3.0%)
* χ2-test.Thus the results of the current study add to the find-
ings of previous research and confirm the pattern of
results that appears to be consistent for a range of ages
of women starting HT. The current EPHT results are
also similar to those reported after the second trial year
of the EPHT trial except for painful intercourse [12]. At
the end of the first trial year, painful intercourse was
improved by HT, whereas at the end of the second trial
year, the effect was reversed [12]. A possible reason for
this could be the decrease in adherence rates between
the first and second years; at the end the first trial year,
the proportion of women taking more than 80% of allo-
cated drugs in treatment arms was 46% whereas at the
end of the second trial year it was 32% [11]. All analyses
were done according to intention-to-treat principle.
The WHQ was used in the Estonian language for the
first time, and it proved to be a useful and sensitive tool
to assess quality of life in this specific age group of
women. In contrast the EuroQoL questionnaire, which
measures generic health related QOL, that was used at
the end of the second trial year of the EPHT trial did not
detect any differences between the trial arms [12]. In-
cluding both menopause specific and generic QOL mea-
sures is recommended for quality of life measurements
in this target group.
To examine the impact of blinding on recruitment,
randomisation occurred before signing the informed
consent. A large number of randomised women declined
their participation and did not enter the trial, but since
this happened before recruitment, it could have not been
related to their treatment allocation. At recruitment,
there were no baseline differences in the prevalence of
symptoms during past two weeks in different trial arms
except for sweating which was reported more often by
women in the non-blind HT arm than in the non-treat-
ment arm [12]. There were no differences between back-
ground characteristics of the women in four trial arms
[10,12]. One of the limitations of this study is that QOL
was not assessed at baseline. We presume that there
were no significant differences between the trial arms in
that aspect due to randomisation. Low adherence rates
may have diluted to some extent the differences between
the trial arms.
The differences in the results of the menstrual problems
(WHQ subscale) between HT and non-HT groups at one
year are likely to reflect vaginal bleeding, caused by HT.
Therefore, they were not regarded irrelevant for postme-
nopausal women and were included in the present ana-
lysis. Previous analysis showed that HT increased the
risk of bleeding substantially [12]. Our questionnaire did
not include questions on other adverse events of HT,
such as breast tenderness, but these have been the most
often cited reasons for non-adherence to HT in earlier
studies [11].
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In the light of previous research in this area, the results
from the EPHT trial confirm that HT is not justified for
treating symptoms other than vasomotor symptoms
among postmenopausal women. Our study shows that
many symptoms that are often attributed to menopause,
such as psychological and physical symptoms, are not
changed by HT and therefore HT should not be recom-
mended as a treatment for these symptoms which are
likely to have other causes.
WHQ allowed a detailed insight on various aspects of
life quality of in this target group. It could be used more
widely in evaluations of medical and non-medical inter-
ventions among peri- and postmenopausal women.
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